Andrew J Bett

This inventor holds 26 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Vaccine Development. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Northwestern University. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew J Bett. Retrieved from https://idiyas.com/inventor/andrew-j-bett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 18)

% Patents Active = 80.8

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 14)

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 176(Granted Patents)

Location History:

Landsdale, PA (US) (2004 - 2023)
Lansdale, PA (US) (2002 - 2024)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Northwestern University

International Aids Vaccine Initiative

patents

6. 1 out of 47

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

RSV RNA Vaccines

Chimeric VSV Vectors

SARS-CoV-2 Spike Proteins

Stabilized RSV F Proteins

Lipid Nanoparticle Adjuvants

Dengue Virus Vaccines

Recombinant Subunit Vaccines

Anti-ADDL Antibodies

Hepatitis C Virus Vaccines

Gene Therapy

Adenovirus Vaccines

Angiogenesis Inhibition

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12453766 - RSV RNA vaccines (2025-10-28),

2. 12311021 - Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins (2025-05-27),

3. 12234265 - Stabilized RSV F proteins and uses thereof (2025-02-25),

4. 11911453 - RSV RNA vaccines (2024-02-27),

5. 11752206 - Herpes simplex virus vaccine (2023-09-12),

6. 11638754 - HPV vaccine (2023-05-02),

7. 11566051 - Stabilized RSV F proteins and uses thereof (2023-01-31),

8. 11464848 - Respiratory syncytial virus vaccine (2022-10-11),

9. 11406706 - Lipid nanoparticle vaccine adjuvants and antigen delivery systems (2022-08-09),

10. 10821175 - Lipid nanoparticle vaccine adjuvants and antigen delivery systems (2020-11-03),

11. 10449243 - Dengue virus vaccine compositions and methods of use thereof (2019-10-22),

12. 10137187 - Recombinant subunit dengue virus vaccine (2018-11-27),

13. 9861692 - Dengue virus vaccine compositions and methods of use thereof (2018-01-09),

14. 9198964 - Recombinant subunit dengue virus vaccine (2015-12-01),

15. 8889138 - Anti-ADDL antibodies and uses thereof (2014-11-18),

Title: The Innovations of Andrew J Bett: Pioneering Vaccines for Viral Diseases

Introduction: Andrew J Bett, a prominent inventor based in Landsdale, PA, has made significant contributions to the field of medicine through his groundbreaking inventions in vaccine technology. With a total of 23 patents to his name, Bett has revolutionized the development of vaccines for viral diseases.

Latest Patents: Among his latest patents, Andrew J Bett has introduced revolutionary RSV (respiratory syncytial virus) RNA vaccines. These vaccines, formulated in lipid nanoparticles, offer promising solutions for combating RSV infections. Additionally, Bett's invention of a Herpes Simplex Virus (HSV) RNA vaccine, also utilizing lipid nanoparticles, demonstrates his commitment to advancing preventive medicine.

Career Highlights: Andrew J Bett has showcased his expertise while working at distinguished companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His tenure at these renowned pharmaceutical firms provided him with the platform to bring his innovative ideas to life and positively impact public health.

Collaborations: Throughout his career, Bett has collaborated with esteemed professionals in the field of vaccine development, including coworkers Danilo R Casimiro and Paul Acton. These collaborations have fostered a culture of innovation and knowledge-sharing, leading to the successful implementation of novel vaccine technologies.

Conclusion: In conclusion, Andrew J Bett's relentless pursuit of excellence in vaccine research has positioned him as a trailblazer in the field of preventive medicine. His dedication to developing cutting-edge solutions for viral diseases underscores his commitment to improving global health outcomes. As he continues to ideate and innovate, Bett's contributions are poised to have a lasting impact on the healthcare landscape.

Profile summary based on public USPTO records.